Jakafi 10 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FQLM0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,365
Award facts
- Contract value 100% obligated
- $12,364.81 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,364.81 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Jakafi 10 mg tablets (60-count). This firm fixed-price delivery order, issued on December 9, 2025, with an ultimate completion date of December 10, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the DLA, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative.
DMS Pharmaceutical Group holds a single-award IDC with a $499.999 billion ceiling value and completion date of December 31, 2036, positioning the company as a critical pharmaceutical supplier for Department of Defense healthcare operations. The PPV-G GEN V program represents a $30.3 billion DLA acquisition strategy designed to provide a comprehensive range of pharmaceuticals—including branded and generic prescription drugs, biologics, and medical consumables—to military healthcare facilities worldwide. This delivery order for Jakafi, a specialty pharmaceutical used in hematologic malignancies and myelofibrosis, exemplifies the vendor's role in fulfilling the diverse and specialized pharmaceutical requirements of the federal military medical system. DMS Pharmaceutical Group is performing as the prime contractor with no identified subcontractors.
Quick answers
Who was awarded contract SPE2DR26FQLM0?
SPE2DR26FQLM0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 9, 2025.
How much is contract SPE2DR26FQLM0 worth?
The government has obligated $12,365 on SPE2DR26FQLM0.
Is contract SPE2DR26FQLM0 an order under another contract?
Yes. SPE2DR26FQLM0 is a delivery order under SPE2DR25D9354, an indefinite delivery contract.
Was contract SPE2DR26FQLM0 competed?
The extent of competition for SPE2DR26FQLM0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award